Cefepime: a rare cause of encephalopathy
A. McNally,A. Pithie,D. Jardine
DOI: https://doi.org/10.1111/j.1445-5994.2012.02800.x
2012-06-01
Abstract:A 70-year-old white woman presented with a 24-h history of dysphasia, myoclonus, stupor and oliguria. Eleven days previously, she had commenced home intravenous cefepime 2 g twice daily for Pseudomonas aeruginosa left heel osteomyelitis. Medical history included type II diabetes mellitus with mild chronic renal impairment (glomerular filtration rate (GFR) ~50–55 mL/min), peripheral vascular disease and right below-knee amputation, neuropathic pain, hypertension, cerebrovascular disease, hepatic cirrhosis secondary to ethanol and steatohepatitis, low-grade myelodysplasia and treated endometrial cancer. Her medications were long-acting morphine (40 mg twice daily), gabapentin, zopiclone, oxazepam, citalopram, doxepin, aspirin, frusemide, cilazapril, paracetamol, metformin, omeprazole and simvastatin. On examination, she was afebrile, dehydrated and confused with expressive dysphasia. Pulse 80/min, blood pressure 153/89 mmHg, respiratory rate 14/min, and oxygen saturations were only 80% on room air. We observed recurrent episodes of myoclonus associated with apnoeic spells lasting up to 10 s. Investigations revealed acute renal failure: creatinine 244 mmol/L, urea 22.4 mmol/L, sodium 135 mmol/L, potassium 6.0 mmol/L and glucose 6.2. Arterial blood gas (on 6 L O2) demonstrated a mixed metabolic and respiratory acidosis: pH 7.08, pCO2 57 mmHg, HCO3 16.1 mmol/L and normal anion gap. Lactate was 0.9 mmol/L. Haemoglobin was 106 g/L, white cell count 8.0 ¥ 10/L, platelet count 139 ¥ 10/L and C-reactive protein 4 mg/L. Alkaline phosphatase was 212 IU/L, Aspartate aminotransferase 72 IU/L, albumin and International Normalised Ratio were normal. Venous ammonia was elevated at 68 mmol/L (11–32 mmol/L). Chest X-ray, electrocardiogram and computed tomography of the head were unremarkable. Cerebrospinal fluid (CSF) analysis was not performed on initial presentation. Initially, the differential diagnoses included drug toxicity secondary to psychotropic medications in the setting of acute renal failure and hepatic encephalopathy. Sepsis was thought to be unlikely. Respiratory function deteriorated, and she required intensive care unit (ICU) admission with ventilator support for 24 h. All usual medications and cefepime were withheld. Over 3 days in the ICU, encephalopathy and myoclonus resolved, and blood chemistry normalised. Intravenous cefepime was restarted 1 day after discharge from ICU at a renal-adjusted dose of 2 g once daily. Over the next 2 days, she redeveloped encephalopathy and myoclonus, and deteriorated, requiring readmission to ICU for ventilation. On this occasion, renal function, CSF analysis and ammonia were normal. Cefepime was stopped indefinitely. She gradually improved and was discharged home 2 months after initial presentation, walking independently. A final diagnosis of cefepime-induced encephalopathy was made. This is the first reported case of this condition in Australasia. Cefepime is an extended-spectrum, fourth-generation cephalosporin used to treat mild-to-severe infections and febrile neutropenia. It undergoes hepatic metabolism but is mainly excreted through renal elimination. The dose with normal renal function is 2 g every 12 h, and dose adjustment is recommended if the GFR is <50 mL/ min. The half-life of cefepime in those with GFR <10 mL/min is approximately five times longer than those with normal renal function. Cefepime-induced encephalopathy has been sporadically reported worldwide over the last decade. Encephalopathy manifests as altered mental status, confusion, hallucinations, cognitive disturbances, myoclonus, seizures or non-convulsive status epilepticus. A review of 42 cases of cefepime-induced encephalopathy most commonly observed confusion with temporospatial disorientation (96%), myoclonus (33%) and seizures (13%) in affected patients. Coma leading to death has been observed. A clear association exists with the presence of renal impairment, an important risk factor. A prospective cohort study over 1 year following 498 patients prescribed cefepime, found 5 out of 111 patients with GFR < 60 mL/min were diagnosed with cefepimeinduced encephalopathy. The mean GFR in those with encephalopathy was 17.2 mL/min, versus 32.6 mL/min in those without encephalopathy (P = 0.025). Sonck et al. undertook a retrospective review of renal failure patients treated with cefepime who developed neurological complications. All eight patients who developed neurological symptoms died within 42 days of becoming symptomatic. Cefepime-induced encephalopathy has also been described in patients with normal renal function and cirrhosis. Advancing patient age and physician unawareness may also increase the risk. The neurotoxic side-effects of beta-lactam antibiotics are probably secondary to suppression of inhibitory neurotransmission mediated through gamma-aminobutyric acid-A receptors. In renal failure, the neurotoxic effects are associated with a rise in the CSF concentration of cefepime. Haemodialysis rapidly removes cefepime from the blood and may be used in patients with encephalopathy and renal impairment, although it does not always improve outcome. Monitoring of plasma cefepime concentration levels has also been proposed. bs_bs_banner